Combined Clinical Trial Results Of A HER2/Neu (E75) Vaccine For Prevention Of Recurrence In High-Risk Breast Cancer Patients

Reviewer: John P. Plastaras, MD, PhD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 14 de diciembre del 2006

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015

Related News

SABCS: Study Examines Dual HER2 Blockade in Breast Cancer

Dec 12, 2013

Initial results show improved pathologic response with combo therapy; survival results expected

SABCS: No Benefit in Extending Trastuzumab in HER2 Breast CA

Dec 10, 2012

In early stage, no improvement in disease-free, overall survival with two years versus one year

Invasive Recurrence Risk Examined for HER2+ Breast CA

Jun 5, 2014

Low risk for T1a tumors; higher risk of distant invasive recurrence for T1b tumors reported at 1.0 cm